Zacks Investment Research downgraded shares of INTERSECT ENT (XENT) from OUTPERFORM to NEUTRAL on January 12, 2015, with a target price of $22.90.
Intersect ENT, Inc. is a commercial drug-device company. The Company's initial products, PROPEL and PROPEL mini, are drug-eluting implants for use in patients with chronic sinusitis. It offers products and therapies for ear, nose, and throat surgeons to improve treatment for their patients with chronic diseases. Intersect ENT, Inc. is headquartered in Menlo Park, California.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on INTERSECT ENT (XENT),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment